Imiquimod approved for AKs

Article

Washington - The U.S. Food and Drug Administration (FDA) has granted marketing approval for Aldara (imiquimod) Cream 5 percent for the treatment of actinic keratoses (AK) on the face or scalp in immunocompetent adults. It is the first immune response modifier (IRM) approved for AK.

Related Videos
Related Content

Expert Perspectives Into Empowering Patients With OTC Relief

September 25th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Expert Insights on Rapid Weight Loss, Semaglutide, and Aesthetic Procedures

September 25th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Holistic Aesthetics Center to Host First Annual Symposium in Middletown, New York

September 24th 2023

Derm In The News: September 17-23

September 23rd 2023

Expert Perspectives Into Empowering Patients With OTC Relief

September 25th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Expert Insights on Rapid Weight Loss, Semaglutide, and Aesthetic Procedures

September 25th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Holistic Aesthetics Center to Host First Annual Symposium in Middletown, New York

September 24th 2023

Derm In The News: September 17-23

September 23rd 2023

Expert Perspectives Into Empowering Patients With OTC Relief

September 25th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Expert Insights on Rapid Weight Loss, Semaglutide, and Aesthetic Procedures

September 25th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Holistic Aesthetics Center to Host First Annual Symposium in Middletown, New York

September 24th 2023

Derm In The News: September 17-23

September 23rd 2023
© 2023 MJH Life Sciences

All rights reserved.